FSSAI suspends Dior Pharmaceuticals’ nutraceutical licence in Punjab
The Food Safety and Standards Authority of India (FSSAI) suspended the nutraceutical manufacturing licence of Dior Pharmaceuticals in Punjab in July 2026. An inspection found serious violations of manufacturing and hygiene standards, along with deficiencies in Good Manufacturing Practices at the plant. The suspension may affect production schedules and lead to audits or further regulatory action if violations persist. Dior Pharmaceuticals must address the concerns, implement corrective measures and reapply for licensure through a formal process. The case highlights stronger regulatory oversight of nutraceutical facilities in India and may prompt other firms to review their quality control, supplier management and hygiene practices.
FSSAI suspended the licence in July 2026 after inspection.
Violations include manufacturing and hygiene standards and GMP deficiencies.
Suspension could affect production and trigger further actions.
Company must address concerns and reapply for licensure.
Signals stricter nutraceutical sector enforcement in India.